Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 1, 2011

Oxford Medical Diagnostics Obtains $1.61M Financing

  • Oxford Medical Diagnostics (OMD), the developer of breath-based tests for metabolic and infectious diseases, reports raising £981,000 (roughly $1.61 million). The funding will be used in the development of its device for the diagnosis and monitoring of type 1 and 2 diabetes.

    By next year, the company aims to bring to market a point-of-care diagnostic that detects the volatile gas acetone, which is reportedly a known marker for both types of diabetes. This test is based on OMD’s CEAS (cavity enhanced absorption spectroscopy) and PES (plasma emission spectroscopy) technologies, and the company is also working on diagnostics for infectious diseases.

    OMD says that it has raised £2.2 million to date. The company also generates revenue from its gas analysis service segment. Besides the CEAS and PES platforms, OMD’s technologies included broadband CEAS. The firm says that it recently signed an R&D agreement with gas analyst specialist Michell Instruments of Ely.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »